Int J Radiat Oncol Biol Phys
Division of Radiation Oncology, New York University Medical Center, NY 10016.
Published: July 1989
The management of patients with pituitary adenomas by radiotherapy alone, using modern techniques of evaluation and current standards of treatment, has not been examined. This is a retrospective review of 29 such patients with nonfunctional or prolactin secreting pituitary macroadenomas. Patients were analyzed by visual fields, hormone levels, and CT scans. All but one patient received a tumor dose of 4500 cGy in 4 to 5 weeks. The tumor was controlled in 26 of 28 (93%) patients for an observed period of 3 to 14 years. Seventeen of 21 (81%) patients with visual impairment experienced normalization or improvement, and seven of ten (70%) patients with hyperprolactinemia achieved normalization of their serum prolactin levels. Post-treatment CT scanning revealed persistent tumor in nine of 17 patients despite clinical improvement. We conclude that: (a) radiotherapy is an effective treatment for these tumors; (b) doses need not exceed 4500 cGy in 25 fractions; (c) radiation is effective for improving vision; (d) radiation can normalize hyperprolactinemia; and (e) tumor regression is variable and unrelated to observed symptom regression.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0360-3016(89)90384-2 | DOI Listing |
Pract Radiat Oncol
February 2025
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.
Purpose: This guideline provides evidence-based recommendations addressing the indications for definitive treatment of primary squamous cell carcinoma of the anal canal and anal margin.
Methods: The American Society for Radiation Oncology convened a task force to address 4 key questions focused on (1) indications for radiation therapy (RT), concurrent systemic therapy and local excision/surgery, (2) appropriate RT techniques, (3) appropriate RT dose-fractionation regimens, target volumes, and dose constraints, and (4) appropriate surveillance strategies after definitive treatment. Recommendations are based on a systematic literature review and created using a predefined consensus-based methodology and system for grading evidence quality and recommendation strength.
Cureus
November 2024
Department of Oncology, Wayne State University School of Medicine, Detroit, USA.
Adaptive radiation therapy is a modern technological advancement that allows radiation treatments to be adjusted daily to account for changes in the patient's anatomy, such as bladder and rectal filling, as well as changes in the tumor volume and position. In this case report, we present a patient with locally advanced cervical cancer who received definitive radiation therapy of 4500 cGy in 25 fractions using the Varian's Ethos system. We observed substantial daily uterine movement, which required re-optimization of each treatment fraction.
View Article and Find Full Text PDFJ Neurooncol
November 2024
Department of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Purpose: To determine the dose-dependent effect of adjuvant radiotherapy on survival for pediatric intracranial ependymomas and explore patient and disease characteristics that experience survival benefit from higher doses.
Methods: Data was accessed from the National Cancer Database. Inclusion criteria was comprised of a diagnosis of non-metastatic intracranial ependymoma, World Health Organization (WHO) grade 2 or 3, surgical resection, adjuvant radiotherapy between 4500-6300 cGy, and non-missing survivorship data.
Brachytherapy
November 2024
Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, PA, 19111, USA. Electronic address:
Objective: We utilized the National Cancer Database (NCDB) to evaluate trends and assess outcomes in radiation therapy (RT) boost modality and total dose among medically inoperable endometrial cancer (EC) patients with locoregional disease.
Methods: Patients with International Federation of Gynecology and Obstetrics (FIGO) stage I - IIIC2 inoperable EC treated with RT ± chemotherapy were analyzed. Practice patterns compared external beam RT (EBRT) versus high-dose-rate brachytherapy (BT) boost and total RT dose (palliative: ≤3000 cGy, definitive low dose [DLD]: 4500 - 6249 cGy, definitive high dose [DHD]: ≥6250 cGy) over time.
BMC Cancer
July 2024
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, SR-201, New York, NY, 10065, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.